In this episode of the podcast, the Oncology Brothers were joined by Dr. Karine Tawagi, a medical oncologist, and Dr. Sia Daneshmand, a urologist, to discuss the current standard of care and treatment options for bladder cancer. The discussion covered various aspects of bladder cancer management, starting from non-muscle invasive bladder cancer to metastatic disease.
Dr. Daneshmand highlighted the importance of categorizing bladder cancer based on risk categories and discussed the use of intravesical chemotherapy for low-grade tumors and the role of BCG in high-grade tumors. Dr. Tawagi emphasized the significance of adequate biopsy and the approval of pembrolizumab for high-risk non-muscle invasive bladder cancer.
The conversation delved into the management of muscle-invasive bladder cancer, including neoadjuvant chemotherapy options for cisplatin-eligible patients and considerations for bladder preservation. The podcast also touched on the evolving landscape of metastatic bladder cancer treatment, with a focus on the groundbreaking EV Pembro regimen and potential second-line treatment options.
The hosts and guests discussed the importance of managing toxicities associated with new treatment modalities like infortumab, sasituzumab, and ertifitinib. They also highlighted the role of ctDNA in assessing treatment response and the need for close monitoring and collaboration among specialty services.
Overall, the episode provided a comprehensive overview of the current approaches to bladder cancer treatment, emphasizing the need for personalized care and ongoing research to improve outcomes for patients.
